A clinical trial exploring the addition of sargramostim to CTLA-4 inhibition combined with PD-1 inhibition in melanoma is ongoing (ECOG-ACRIN6141; NCT02339571) [102] (Table 4). Here, CTLA4 is linked to melanoma.